{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:59:15Z","timestamp":1782471555216,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Bevacizumab is an anti-angiogenetic treatment that can be used in patients with recurrent glioblastoma, but there are limited and controversial data on the optimal dose and schedule, associated toxicities and survival benefits of different doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective analysis of patients with recurrent <jats:italic>IDH<\/jats:italic>wt glioblastoma treated with bevacizumab at the Veneto Institute of Oncology was performed. Patients received bevacizumab in 2 different schedules (5 mg\/kg or 10 mg\/kg q2w), as monotherapy or in combination with chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>81 patients were analyzed, 33 received bevacizumab 5 mg\/Kg, 48 received bevacizumab 10 mg\/Kg. Median PFS was 4 months in both patients treated with 5 mg\/kg and those treated with 10 mg\/kg (p-value=0.08), median OS was 5 months in patients treated with 5 mg\/kg and 7 months in those treated with 10 mg\/kg (p-value=0.10). There was no difference in the use of steroid therapy between the two groups. The incidence of adverse events was not statistically different.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There was no statistically significant difference in survival, PFS, response, toxicity and steroid reduction between the two different doses. These results may support the use of lower doses of the drug with comparable benefit for patients and with additional advantage in terms of health care costs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-04992-4","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:47:16Z","timestamp":1741614436000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience"],"prefix":"10.1007","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-0537","authenticated-orcid":false,"given":"Giulia","family":"Cerretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Librizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pintacuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Salvalaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zoccarato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pasqualetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Volpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"4992_CR1","doi-asserted-by":"crossref","unstructured":"Da LN (2017) High-grade gliomas. Continuum (Minneapolis Minn) 23(6). Neuro-oncology10.1212\/CON.0000000000000554","DOI":"10.1212\/CON.0000000000000554"},{"issue":"8","key":"4992_CR2","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/biomedicines10081927","volume":"10","author":"A Leone","year":"2022","unstructured":"Leone A, Colamaria A, Fochi NP et al (2022) Recurrent glioblastoma treatment: state of the Art and future perspectives in the precision medicine era. Biomedicines 10(8):1927. https:\/\/doi.org\/10.3390\/biomedicines10081927","journal-title":"Biomedicines"},{"issue":"3","key":"4992_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/187152709788680706","volume":"8","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC, Raizer J (2009) Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord Drug Targets 8(3):184\u2013194. https:\/\/doi.org\/10.2174\/187152709788680706","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"4992_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N (2023) Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov 22(6):476\u2013495. https:\/\/doi.org\/10.1038\/s41573-023-00671-z","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4992_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4992_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PPO.0b013e3182431c6f","volume":"18","author":"ER Gerstner","year":"2012","unstructured":"Gerstner ER, Batchelor TT (2012) Antiangiogenic therapy for glioblastoma. Cancer J 18(1):45\u201350. https:\/\/doi.org\/10.1097\/PPO.0b013e3182431c6f","journal-title":"Cancer J"},{"key":"4992_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000467379","volume":"31","author":"J Jo","year":"2018","unstructured":"Jo J, Wen PY (2018) Antiangiogenic therapy of High-Grade gliomas. Prog Neurol Surg 31:180\u2013199. https:\/\/doi.org\/10.1159\/000467379","journal-title":"Prog Neurol Surg"},{"issue":"28","key":"4992_CR8","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with Irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"issue":"2","key":"4992_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/11203890-000000000-00000","volume":"70","author":"MD Moen","year":"2010","unstructured":"Moen MD (2010) Bevacizumab: in previously treated glioblastoma. Drugs 70(2):181\u2013189. https:\/\/doi.org\/10.2165\/11203890-000000000-00000","journal-title":"Drugs"},{"issue":"3","key":"4992_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12094-011-0642-9","volume":"13","author":"C Bala\u00f1\u00e1","year":"2011","unstructured":"Bala\u00f1\u00e1 C, Etxaniz O, Bug\u00e9s C, Mart\u00ednez A (2011) Approval denied by the European medicines agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good Idea or a grave error? Clin Transl Oncol 13(3):209\u2013210. https:\/\/doi.org\/10.1007\/s12094-011-0642-9","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"4992_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus Irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740\u2013745. https:\/\/doi.org\/10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"issue":"22","key":"4992_CR12","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1002\/cncr.25462","volume":"116","author":"JJ Raizer","year":"2010","unstructured":"Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22):5297\u20135305. https:\/\/doi.org\/10.1002\/cncr.25462","journal-title":"Cancer"},{"issue":"9","key":"4992_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/now035","volume":"18","author":"AA Brandes","year":"2016","unstructured":"Brandes AA, Finocchiaro G, Zagonel V et al (2016) AVAREG: a phase II, randomized, noncomparative study of Fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol 18(9):1304\u20131312. https:\/\/doi.org\/10.1093\/neuonc\/now035","journal-title":"Neuro Oncol"},{"issue":"30","key":"4992_CR14","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus Irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722\u20134729. https:\/\/doi.org\/10.1200\/JCO.2007.12.2440","journal-title":"J Clin Oncol"},{"issue":"9","key":"4992_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AME et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"},{"issue":"11","key":"4992_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","volume":"17","author":"KM Field","year":"2015","unstructured":"Field KM, Simes J, Nowak AK et al (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17(11):1504\u20131513. https:\/\/doi.org\/10.1093\/neuonc\/nov104","journal-title":"Neuro Oncol"},{"issue":"3","key":"4992_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-016-2195-9","volume":"129","author":"SP Weathers","year":"2016","unstructured":"Weathers SP, Han X, Liu DD et al (2016) A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487\u2013494. https:\/\/doi.org\/10.1007\/s11060-016-2195-9","journal-title":"J Neurooncol"},{"issue":"2","key":"4992_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-009-9957-6","volume":"96","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96(2):259\u2013269. https:\/\/doi.org\/10.1007\/s11060-009-9957-6","journal-title":"J Neurooncol"},{"key":"4992_CR19","doi-asserted-by":"publisher","first-page":"106239","DOI":"10.1016\/j.clineuro.2020.106239","volume":"198","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo L, Li X, Liu R, Ren C, Du S (2020) Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: which one is better? A meta-analysis. Clin Neurol Neurosurg 198:106239. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106239","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"4992_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11060-015-2025-5","volume":"127","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal DT, Mendel L, Bokstein F (2016) The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 127(3):493\u2013502. https:\/\/doi.org\/10.1007\/s11060-015-2025-5","journal-title":"J Neurooncol"},{"issue":"1","key":"4992_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11060-014-1693-x","volume":"122","author":"VA Levin","year":"2015","unstructured":"Levin VA, Mendelssohn ND, Chan J et al (2015) Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 122(1):145\u2013150. https:\/\/doi.org\/10.1007\/s11060-014-1693-x","journal-title":"J Neurooncol"},{"issue":"1","key":"4992_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-017-2553-2","volume":"135","author":"A Ajlan","year":"2017","unstructured":"Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L (2017) Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 135(1):99\u2013105. https:\/\/doi.org\/10.1007\/s11060-017-2553-2","journal-title":"J Neurooncol"},{"issue":"21","key":"4992_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ (2017) Response assessment in Neuro-Oncology clinical trials. J Clin Oncol 35(21):2439\u20132449. https:\/\/doi.org\/10.1200\/JCO.2017.72.7511","journal-title":"J Clin Oncol"},{"key":"4992_CR24","unstructured":"Common Terminology (2017)"},{"issue":"8","key":"4992_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4992_CR26","unstructured":"R Core Team A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Published online 2024. https:\/\/www.R-project.org\/"},{"issue":"11","key":"4992_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131\u20131138. https:\/\/doi.org\/10.1634\/theoncologist.2009-0121","journal-title":"Oncologist"},{"key":"4992_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/sni.sni_264_17","volume":"9","author":"AJ Franke","year":"2018","unstructured":"Franke AJ, Skelton WP, Woody LE et al (2018) Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int 9:133. https:\/\/doi.org\/10.4103\/sni.sni_264_17","journal-title":"Surg Neurol Int"},{"issue":"2","key":"4992_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cam4.2616","volume":"9","author":"JP Gleeson","year":"2020","unstructured":"Gleeson JP, Keane F, Keegan NM et al (2020) Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma. Cancer Med 9(2):469\u2013475. https:\/\/doi.org\/10.1002\/cam4.2616","journal-title":"Cancer Med"},{"issue":"3","key":"4992_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11060-023-04248-z","volume":"161","author":"JM Melhem","year":"2023","unstructured":"Melhem JM, Tahir A, Calabrese E et al (2023) Dose-dependent efficacy of bevacizumab in recurrent glioblastoma. J Neurooncol 161(3):633\u2013641. https:\/\/doi.org\/10.1007\/s11060-023-04248-z","journal-title":"J Neurooncol"},{"issue":"17","key":"4992_CR31","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.22.01579","volume":"41","author":"G Youssef","year":"2023","unstructured":"Youssef G, Rahman R, Bay C et al (2023) Evaluation of standard response assessment in Neuro-Oncology, modified response assessment in Neuro-Oncology, and immunotherapy response assessment in Neuro-Oncology in newly diagnosed and recurrent glioblastoma. J Clin Oncol 41(17):3160\u20133171. https:\/\/doi.org\/10.1200\/JCO.22.01579","journal-title":"J Clin Oncol"},{"issue":"33","key":"4992_CR32","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: update to the response assessment in Neuro-Oncology criteria for High- and Low-Grade gliomas in adults. J Clin Oncol 41(33):5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"issue":"11","key":"4992_CR33","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jjco\/hyz125","volume":"49","author":"N Motoo","year":"2019","unstructured":"Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R (2019) Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study. Jpn J Clin Oncol 49(11):1016\u20131023. https:\/\/doi.org\/10.1093\/jjco\/hyz125","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"4992_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bulcan.2018.07.010","volume":"105","author":"L Sirven-Villaros","year":"2018","unstructured":"Sirven-Villaros L, Bourg V, Suissa L et al (2018) Bevacizumab: is the lower the better for glioblastoma patients in progression? Bull Cancer 105(12):1135\u20131146. https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.010","journal-title":"Bull Cancer"},{"issue":"12","key":"4992_CR35","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1634\/theoncologist.2010-0105","volume":"15","author":"JJ Vredenburgh","year":"2010","unstructured":"Vredenburgh JJ, Cloughesy T, Samant M et al (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329\u20131334. https:\/\/doi.org\/10.1634\/theoncologist.2010-0105","journal-title":"Oncologist"},{"issue":"11","key":"4992_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamaneurol.2023.3284","volume":"80","author":"A Salvalaggio","year":"2023","unstructured":"Salvalaggio A, Pini L, Gaiola M et al (2023) White matter tract density index prediction model of overall survival in glioblastoma. JAMA Neurol 80(11):1222\u20131231. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3284","journal-title":"JAMA Neurol"},{"key":"4992_CR37","doi-asserted-by":"publisher","first-page":"1061502","DOI":"10.3389\/fonc.2023.1061502","volume":"13","author":"JL Boxerman","year":"2023","unstructured":"Boxerman JL, Snyder BS, Barboriak DP, Schmainda KM (2023) Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: results from ACRIN 6677\/RTOG 0625. Front Oncol 13:1061502. https:\/\/doi.org\/10.3389\/fonc.2023.1061502","journal-title":"Front Oncol"},{"issue":"8","key":"4992_CR38","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/neuonc\/nou364","volume":"17","author":"KM Schmainda","year":"2015","unstructured":"Schmainda KM, Zhang Z, Prah M et al (2015) Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677\/RTOG 0625 multicenter trial. Neuro Oncol 17(8):1148\u20131156. https:\/\/doi.org\/10.1093\/neuonc\/nou364","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04992-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:44:27Z","timestamp":1748249067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04992-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4992"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04992-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective observational study, no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}